Clinical Research Directory
Browse clinical research sites, groups, and studies.
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Sponsor: Barbara Ann Karmanos Cancer Institute
Summary
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.
Official title: Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET)
Key Details
Gender
All
Age Range
18 Years - 120 Years
Study Type
INTERVENTIONAL
Enrollment
Not specified
Start Date
2009-09
Completion Date
2028-05
Last Updated
2025-07-08
Healthy Volunteers
No
Conditions
Interventions
3'-deoxy-3'-[18F]fluorothymidine
The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. Blood may be withdrawn (through the catheters) up to a total volume of 30 milliliters (or 2 tablespoons) for each scan. A urine sample may be collected at the end of the imaging of the tracer compound to analyze its breakdown products.
Locations (1)
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States